公开(公告)号：US20160083359A1

公开(公告)日：2016-03-24

申请号：US14948775

申请日：2015-11-23

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  André Faldt ,  Arne Mørk ,  Heidi Lopez De Diego ,  René Holm ,  Tine Bryan Stensbøl ,  Lone Munch Ringgard ,  Michael J. Mealy ,  Michael Harold Rock ,  Jørgen Brodersen ,  Morten Jørgensen ,  Nicholas Moore

IPC: C07D295/096

CPC classification number: A61K31/495 ,  A61K9/14 ,  A61P25/22 ,  C07D295/096 ,  Y10T428/2982

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Abstract translation: 1- [2-（2,4-二甲基苯基硫烷基）苯基]哌嗪显示出对SERT，5-HT3和5-HT1A的有效活性，并且可以用于治疗认知障碍，特别是抑郁症患者。

公开(公告)号：US20180161321A1

公开(公告)日：2018-06-14

申请号：US15661392

申请日：2017-07-27

Applicant: H. Lundbeck A/S ,  Takeda Pharmaceuticals U.S.A., Inc.

Inventor： Nicholas Moore ,  Marianne Dragheim ,  Aneil Batra ,  Jin Chon

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

公开(公告)号：US20210093631A1

公开(公告)日：2021-04-01

申请号：US15930014

申请日：2020-05-12

Applicant: H. Lundbeck A/S

Inventor： Nicholas Moore ,  Marianne Dragheim

IPC: A61K31/495

Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

公开(公告)号：US20150005318A1

公开(公告)日：2015-01-01

申请号：US14481000

申请日：2014-09-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Arne Mork ,  Nicholas Moore ,  Tine Bryan Stensbol

IPC: A61K31/495

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

Abstract translation: 本公开涉及治疗选自阿尔茨海默氏病，认知障碍和注意缺陷多动障碍（ADHD）的疾病的方法。 该方法包括向有需要的患者施用治疗有效量的化合物I或其药学上可接受的盐，其中化合物I是1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪。

公开(公告)号：US20140377363A1

公开(公告)日：2014-12-25

申请号：US14480949

申请日：2014-09-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Arne Mork ,  Nicholas Moore ,  Tine Bryan Stensbol

IPC: C07D295/096 ,  A61K31/495 ,  A61K9/14

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

Abstract translation: 本公开涉及治疗选自情感障碍，抑郁症，重度抑郁障碍，焦虑症，一般焦虑症，社会焦虑症，强迫症，惊恐障碍和惊恐发作的疾病的方法。 该方法包括向有需要的患者施用治疗有效量的化合物I或其药学上可接受的盐，其中化合物I是1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪。

公开(公告)号：US09744166B2

公开(公告)日：2017-08-29

申请号：US15043167

申请日：2016-02-12

Applicant: H. Lundbeck A/S

Inventor： Nicholas Moore ,  Marianne Dragheim

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

公开(公告)号：US20240082239A1

公开(公告)日：2024-03-14

申请号：US18130749

申请日：2023-04-04

Applicant: H. Lundbeck A/S

Inventor： Nicholas Moore ,  Marianne Dragheim

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

公开(公告)号：US11628166B2

公开(公告)日：2023-04-18

申请号：US15930014

申请日：2020-05-12

Applicant: H. Lundbeck A/S

Inventor： Nicholas Moore ,  Marianne Dragheim

IPC: A61K31/495

Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

公开(公告)号：US20160228430A1

公开(公告)日：2016-08-11

申请号：US15043167

申请日：2016-02-12

Applicant: H. Lundbeck A/S ,  Takeda Pharmaceuticals U.S.A., Inc.

Inventor： Nicholas Moore ,  Marianne Dragheim

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

Abstract translation: 提供1- [2-（2,4-二甲基苯基硫烷基）苯基]哌嗪及其药学上可接受的盐的新药用途。

公开(公告)号：US20140315921A1

公开(公告)日：2014-10-23

申请号：US14326725

申请日：2014-07-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Andre Faldt ,  Arne Mork ,  Heidi Lopez de Diego ,  Rene Holm ,  Tine Bryan Stensbol ,  Nicholas Moore

IPC: C07D295/096

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.

Abstract translation: 本公开涉及结晶形式的1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪或其药学上可接受的盐。